Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

NCT00750555 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped PI Law left Geisinger-study terminated prematurely - 4 patients enrolled

Conditions

Head and Neck Cancer

Interventions

DRUG: Erlotinib

Sponsor

Geisinger Clinic

Collaborators

[object Object]